Abstract: A light system based on at least two chips, in particular LEDs containing chips may include at least one first chip capable of emitting a primary radiation, a layer containing a phosphor mounted in front of the first chip, for converting the primary radiation of the first chip into secondary radiation, at least one second chip capable of emitting a second primary radiation with a greater wavelength than the primary radiation, wherein the layer is arranged spaced apart from the first chip, wherein the second chip is arranged in such a way that its radiation is substantially not absorbed by the phosphor.

Abstract: A sensor arrangement for sensing movement gestures on a motor vehicle with a capacitive sensor arrangement and at least one control and evaluation device which is coupled to the sensor arrangement and which senses a change in the capacitance of the sensor arrangement with respect to a reference potential. A user can use a part of his body, for example his foot, to make a gesture in the sensing range of the sensors for activating a tailgate. At least two sensor electrode arrangements are arranged at spatially offset positions on the motor vehicle. The sensor electrodes are embodied as elongate electrode arrangements and are arranged with the same spatial orientation. One of the sensor electrodes is longer than the other. The relatively long sensor electrode extends beyond the relatively short sensor electrode on both sides in the longitudinal direction.

Abstract: The use of products having enzymatic activity for the preparation of a food, including feed, inducing, when consumed, antisecretory proteins and the foods thus prepared. The products having enzymatic activity may for example be malted cereals.

Abstract: The present invention relates to the use of antisecretory factors, such as antisecretory proteins, homologues, derivatives and/or fragments thereof having antisecretory activity, for the manufacture of a pharmaceutical composition for use in the treatment and/or prevention of intraocular hypertension. The invention thus relates to the use of pharmaceutical compositions comprising antisecretory factors in the treatment and/or prevention of intraocular hypertension, which is preferably characterized by hampered outflow of body fluid resulting in elevated pressure in the eye. The invention provides for a novel approach for treating and/or preventing such a condition turning the intraocular pressure to an acceptable level, optionally 21 mm Hg, or less.

Abstract: Various embodiments relate to an optoelectronic component, including a carrier element, on which at least one optoelectronic semiconductor chip is arranged, and a cover, which is mounted on the carrier element in a region extending circumferentially around the semiconductor chip and together with the carrier element forms a sealed cavity in which the at least one optoelectronic semiconductor chip is arranged in an inert gas.

Abstract: An optoelectronic component includes a layer sequence having an active region that emits primary electromagnetic radiation, wherein the primary electromagnetic radiation has a wavelength of 430 nm to 470 nm, a conversion material arranged in a beam path of the primary electromagnetic radiation and at least partly converts the primary electromagnetic radiation into a secondary electromagnetic radiation, wherein the conversion material includes a first phosphor having general composition A3B5O12, wherein A is a combination of Lu and Ce, and wherein B is a combination of Al and Ga.

Abstract: An LED light system may include a primary LED radiation source, in particular at least one blue- or UV-emitting semiconductor element, wherein a first dome of transparent or translucent material, which acts as a conversion element, is placed in front of the primary light source in the emission direction, wherein at least a part of the surface of the first dome is divided into at least two regions of different types, which comprise luminescent materials, the at least two regions including different luminescent materials for the conversion.

Abstract: The present invention relates to the use of an antisecretory protein or homologues thereof having the same properties, or certain fragments thereof in the manufacture of a medicament or a medical food for inducing improved rescue of injured or diseased nervous tissue, proliferation, apoptosis, differentiation and/or migration of an embryonic stem cell, adult stem cell, progenitor cell and/or a cell derived from a stem cell or progenitor cell, for treating a condition characterized by or associated with loss and/or gain of cells. In a preferred embodiment, the condition is a neurotrauma or a condition or disease of the CNS and/or PNS and/or ANS, for example, Alzheimer's disease.

Abstract: A closing system for doors having a container provided in a handle. The container has a touch surface that is placed in a window-type recess of the handle, and a switching element that is arranged in the container can be actuated by the touch surface. The switching element is used to switch the control electronics of the closing system between two states, namely a state that prevents opening of the door and a state that allows the door to be opened.

Abstract: A sensor arrangement for sensing movement gestures on a motor vehicle with a capacitive sensor arrangement and at least one control and evaluation device which is coupled to the sensor arrangement and which senses a change in the capacitance of the sensor arrangement with respect to a reference potential. A user can use a part of his body, for example his foot, to make a gesture in the sensing range of the sensors for activating a tailgate. At least two sensor electrode arrangements are arranged at spatially offset positions on the motor vehicle. The sensor electrodes are embodied as elongate electrode arrangements and are arranged with the same spatial orientation. One of the sensor electrodes is longer than the other. The relatively long sensor electrode extends beyond the relatively short sensor electrode on both sides in the longitudinal direction.

Abstract: A radiation-emitting component includes: a radiation source containing semiconductor materials which emits first radiation of a first wavelength when in operation; a transparent body including a matrix material and an inorganic filler and arranged at least in part in the beam path of the first radiation; and a converter material arranged at least in part in the beam path of the first radiation and which converts first radiation at least in part into second radiation of a second, longer wavelength.

Abstract: A light system based on at least two chips, in particular LEDs containing chips, wherein a means for at least partially converting the radiation of a first chip is provided, wherein a layer containing a phosphor as conversion means is mounted in front of a first chip intended for the conversion, which phosphor-containing layer convers at least some of the primary radiation of the first chip into secondary radiation, wherein the second chip emits radiation with a greater wavelength than the first chip, wherein the layer is arranged spaced apart from the first chip, wherein the second chip is arranged in such a way that its radiation is substantially not absorbed by the phosphor.

Abstract: The present invention relates to the use of an antisecretory protein, derivative, homologue, and/or fragment thereof, having equivalent activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of dysfunction, e.g. abnormal function, hypo- or hyper-function of lipid rafts, receptors and/or caveolae. A dysfunction of lipid rafts, receptors and/or caveolae may be caused by or be a cause of a variety of other conditions, which are also encompassed by the present invention, such as vascular, and lung dysfunctions, and/or endocrine disorders, e.g. diabetes and related disorders. Furthermore, the invention relates to a method for the treatment and/or prevention of dysfunction of lipid rafts and/or caveolae in a mammal in need thereof.

Abstract: The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof.

Abstract: The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof.

Abstract: The present invention relates to the use of antisecretory factors, such as antisecretory proteins, homologues, derivatives and/or fragments thereof having antisecretory activity, for the manufacture of a pharmaceutical composition for use in the treatment and/or prevention of intraocular hypertension. The invention thus relates to the use of pharmaceutical compositions comprising antisecretory factors in the treatment and/or prevention of intraocular hypertension, which is preferably characterized by hampered outflow of body fluid resulting in elevated pressure in the eye. The invention provides for a novel approach for treating and/or preventing such a condition turning the intraocular pressure to an acceptable level, optionally 21 mm Hg, or less.

Abstract: The present invention relates to the use of antisecretory factors, such as antisecretory proteins, homologues, derivatives and/or fragments thereof having antisecretory activity, for the manufacture of a pharmaceutical composition for use in the treatment and/or prevention of intraocular hypertension. The invention thus relates to the use of pharmaceutical compositions comprising antisecretory factors in the treatment and/or prevention of intraocular hypertension, which is preferably characterized by hampered outflow of body fluid resulting in elevated pressure in the eye. The invention provides for a novel approach for treating and/or preventing such a condition turning the intraocular pressure to an acceptable level, optionally 21 mm Hg, or less.

Abstract: A conversion LED with a chip which emits primary blue radiation, and a layer containing luminescent substance upstream of the chip which converts at least part of the primary radiation of the chip into secondary radiation, wherein a first garnet A3B5O12:Ce yellow-green emitting luminescent substance and a second nitride silicate M2X5Y8:D orange-red emitting luminescent substance is used, wherein the peak wavelength of the primary radiation is in the range of 430 to 450 nm, in particular of up to 445 nm, while the first luminescent substance is a garnet with the cation A=Lu or a mixture of Lu, Y with up a Y fraction of up to 30%, and wherein B has fractions of both Al and Ga, while the second luminescent substance is a nitride silicate which contains both Ba and Sr as cation M, and in which the doping consists of Eu, wherein the second luminescent substance contains 35 to 75 mol.-% Ba for the component M, remainder is Sr, where X=Si and Y=N.

Abstract: A conversion LED comprising a chip which emits primary radiation and, positioned upstream of the chip, a luminescent substance-containing layer which converts at least some of the primary radiation of the chip into secondary radiation, wherein a first yellow-green emitting luminescent substance of the A3B5O12:Ce garnet type and a second orange-red emitting luminescent substance of the MAlSiN3:Eu calsine type is used, wherein the peak wavelength of the primary radiation lies in the 435 to 455 nm range, the first luminescent substance being a garnet having essentially the cation A=Lu or Lu in combination with Y, and B simultaneously having fractions of Al and Ga, while the second luminescent substance is of the basic MAlSiN3:Eu type containing Ca as M with a fraction of at least 80%, in particular at least 90%, preferably at least 95%, where M is Ca alone or predominantly Ca and the remainder of M may be Sr, Ba, Mg, Li or Cu, in each case alone or in combination, and wherein some of the Al up to 20%, preferably

Abstract: The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition.